Globus Medical (GMED)

• Market cap: $10.9B
• 1 day: -4.56%
• 5 days: -4.90%
• 1 month: -13.13%
• 3 months: -5.45%
• 6 months: 15.36%
• Year to date: -1.89%
• 1 year: 45.96%
• 5 years: 45.04%
• 10 years: 217.06%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.

Employees: 5,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 98 | Existing positions closed: 42

110% more call options, than puts

Call options by funds: $24.5M | Put options by funds: $11.7M

12% more repeat investments, than reductions

Existing positions increased: 162 | Existing positions reduced: 145

11% more capital invested

Capital invested by funds: $7.79B [Q3] → $8.68B (+$893M) [Q4]

8% more funds holding

Funds holding: 443 [Q3] → 478 (+35) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 18 [Q3] → 18 (+0) [Q4]

4.12% less ownership

Funds ownership: 96.39% [Q3] → 92.27% (-4.12%) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $90 12% upside
• Avg. target: $98 22% upside
• High target: $115 43% upside

8 analyst ratings

• positive: 6 75%
• neutral: 2 25%
• negative: 0 0%

Stifel Mathew Blackman 53% 1-year accuracy 9 / 17 met price target	17% upside $94	Buy Maintained	21 Feb 2025
Wells Fargo Vik Chopra 83% 1-year accuracy 10 / 12 met price target	16% upside $93	Overweight Maintained	21 Feb 2025
Canaccord Genuity William Plovanic 67% 1-year accuracy 33 / 49 met price target	26% upside $101	Buy Maintained	10 Jan 2025
B of A Securities Craig Bijou 50% 1-year accuracy 4 / 8 met price target	21% upside $97	Neutral Upgraded	9 Jan 2025
Truist Securities Richard Newitter 77% 1-year accuracy 33 / 43 met price target	12% upside $90	Hold Maintained	18 Dec 2024